Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunology
New data from X.F. Wang et al illuminate research in cancer vaccines immunology
July 22nd, 2008
A report, 'Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients,' is newly published data in The Journal of Immunology. According to a study from Paris, France, "Because of the wide distribution of the survivin Ag in a variety of tumors, we have investigated the survivin-specific CD4+ T cell response in healthy donors and cancer patients. Screening of the entire sequence of survivin for HLA class II binding led to the identification of seven HLA-DR promiscuous peptides, including four HLA-DP4 peptides." "All of the peptides were able to prime in vitro...
Source: Cancer Weekly (2008-07-22)
|
